Success Metrics

Clinical Success Rate

50.0%

Based on 1 completed trials

Completion Rate

50%(1/2)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Terminated

1(33%)

Phase Distribution

Ph early_phase_1

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Early Phase 1First-in-human

3(100.0%)

Highest Phase Reached

Early Phase 1

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(1)

Terminated(2)

Detailed Status

Completed1

Terminated1

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

50.0%

Most Advanced

Early Phase 1

Trials by Phase

Early Phase 13 (100.0%)

Trials by Status

completed133%

terminated133%

withdrawn133%

Recent Activity

0 active trials

Showing 3 of 3

terminatedearly_phase_1

Topotecan in Glioma Undergoing A Clinically-Indicated Surgical Resection

NCT02500459

withdrawnearly_phase_1

Intratumorally-Administered Topotecan Using CED in High Grade Glioma Undergoing Stereotactic Biopsy

NCT03193463

completedearly_phase_1

Topotecan Using Convection-Enhanced Delivery (CED) in High Grade Glioma

NCT02278510

Clinical Trials (3)

Showing 3 of 3 trials

NCT02500459Early Phase 1

Topotecan in Glioma Undergoing A Clinically-Indicated Surgical Resection

Terminated

NCT03193463Early Phase 1

Intratumorally-Administered Topotecan Using CED in High Grade Glioma Undergoing Stereotactic Biopsy

Withdrawn

NCT02278510Early Phase 1

Topotecan Using Convection-Enhanced Delivery (CED) in High Grade Glioma

Completed

All 3 trials loaded

Drug Details

Intervention Type: DEVICE
Total Trials: 3